FIELD: medicine.
SUBSTANCE: invention relates to methods of treating skin diseases. Disclosed is a method of treating chronic spontaneous urticaria (CSU), comprising administering to a subject in need thereof a daily dose of approximately 10 mg to approximately 100 mg of a compound of formula
(I),
where the term "approximately" means +/−10%.
EFFECT: invention provides safe and effective treatment of spontaneous chronic urticaria.
18 cl, 11 dwg, 10 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF CHRONIC SPONTANEOUS URTICARIA, USING LIGELIZUMAB | 2019 |
|
RU2783540C2 |
| LTA4H INHIBITORS FOR TREATING PURULENT HYDRADENITIS | 2020 |
|
RU2821362C2 |
| COMBINATION OF PI3 KINASE INHIBITOR WITH PACLITAXEL FOR USE IN TREATMENT OR PREVENTION OF HEAD AND NECK CANCER | 2014 |
|
RU2672555C2 |
| USE OF NK-1 RECEPTOR ANTAGONIST SERLOPITANT IN PRURITUS | 2014 |
|
RU2666219C2 |
| METHODS OF TREATING DISEASES ASSOCIATED WITH S1P1 RECEPTOR | 2021 |
|
RU2821032C1 |
| PHARMACEUTICAL COMBINATIONS | 2017 |
|
RU2759669C2 |
| TREATING MALIGNANT TUMORS USING PIZ-KINASE ISOFORM MODULATORS | 2014 |
|
RU2705204C2 |
| THERAPEUTIC COMPOUNDS AND COMPOSITIONS | 2019 |
|
RU2813780C2 |
| METHODS FOR TREATMENT OF LYMPHOMA | 2019 |
|
RU2784243C2 |
| METHODS FOR TREATING SEVERE ATOPIC DERMATITIS BY ADMINISTERING AN IL-4R INHIBITOR | 2017 |
|
RU2759630C2 |
